Tech Center 1600 • Art Units: 1625 1674
This examiner grants 73% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17794003 | MECHANOCHEMICAL SNAr REACTIONS | Non-Final OA | nChain Licensing AG |
| 18547871 | DEVELOPMENT OF PRMT-TARGETING THERAPY TO ENHANCE EGFR-TARGETING DRUG EFFICACY IN NSCLC | Non-Final OA | The Regents of the University of California |
| 18111350 | RESPONSE-GUIDED HCV THERAPY | Non-Final OA | Emory University |
| 19365360 | OPHTHALMIC FORMULATIONS | Non-Final OA | PELTHOS THERAPEUTICS INC. |
| 18853224 | IMMUNE MODULATORY AGENTS | Non-Final OA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18700643 | METHODS OF TREATING DISEASES ASSOCIATED WITH SENESCENT CELL ACCUMULATION | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18604926 | PHARMACEUTICAL COMPOSITIONS COMPRISING APRACLONIDINE FOR OCULAR REDNESS RELIEF | Non-Final OA | ALCON INC. |
| 17760181 | Agent For Treating Or Preventing Pancreatic Fistula | Non-Final OA | NOF CORPORATION |
| 17836814 | ORAL PRODUCTS WITH REDUCED IRRITATION | Final Rejection | NICOVENTURES TRADING LIMITED |
| 18856717 | NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE AND N-PROPYL-AZETIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Non-Final OA | SANOFI |
| 17776922 | METHODS OF INDUCING OR ENHANCING FARNESOID X RECEPTOR (FXR)-MEDIATED TRANSCRIPTIONAL RESPONSE | Final Rejection | YALE UNIVERSITY |
| 18777339 | Benzimidazole Pyridine Derivatives | Non-Final OA | Hoffmann-La Roche Inc. |
| 18248232 | TRUXILLIC ACID MONOESTER-DERIVATIVES AS SELECTIVE FABP5 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Non-Final OA | The Research Foundation for The State University of New York |
| 18689222 | METHOD FOR PRODUCING COMPOUND | Non-Final OA | Mitsubishi Gas Chemical Company, Inc. |
| 18573813 | COMPOUNDS FOR MODULATING MYCOBACTERIUM TUBERCULOSIS RESPONSE | Non-Final OA | Rutgers, The State University of New Jersey |
| 17787964 | METHOD FOR PRODUCING SOLID ELECTROLYTE | Final Rejection | IDEMITSU KOSAN CO.,LTD. |
| 18255749 | OIL-IN-WATER EMULSIFIED COMPOSITION | Non-Final OA | KAO CORPORATION |
| 17800049 | HETEROCYCLIC DERIVATIVES AS TRMP8 ANTAGONISTS | Non-Final OA | Givaudan SA |
| 18267925 | AMORPHOUS SOLID DISPERSIONS | Non-Final OA | UCB Biopharma SRL |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy